NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Herbal Transdermal Wellness Patch Category Examined as Consumers Compare Prescription GLP-1 Costs With Non-Prescription Alternatives Ahead of New Year Weight Loss SeasonDisclaimer: This article is for informational purposes only. It is not medical advic... Read more
Benzinga - Dec 26
The FDA has approved the first-ever Wegovy pill for weight loss, with the oral GLP-1 offering a 16.6% average weight reduction as a needle-free alternative. Read more
Fox News - Dec 23
On Monday, the US Food and Drug Administration approved a daily pill version of Novo Nordisk’s weight-loss drug Wegovy. CNN's Jacqueline Howard explains when it will be available and how much it could cost. Discover more videos, including live streams and exclusive storytelling, on our Watch page. Read more
Cnn - Dec 23
This launch—and the recent cagrisema filing—should help Novo regain its footing against Lilly. Read more
Morningstar - Dec 23
The approval of Novo Nordisk's (NYSE:NVO)oral Wegovy is bringing new interest to health care and pharmaceutical ETFs that provide access to the growing GLP-1 market without requiring investors to choose one specific company.• What should traders watch with XLV?Broad funds like the Health Care Sel... Read more
Benzinga - Dec 23Wegovy's new pill has been approved in the US, offering a needle-free option with a lower starting price than injections. Read more
Insider - Dec 23
U.S. regulators have approved a pill version of the weight-loss drug Wegovy, a boon for drugmaker Novo Nordisk Read more
The Independent - Dec 23
Despite the widespread popularity of new weight-loss medications, research suggests a non-drug alternative is significantly more effective for lasting results. Read more
Mail Online - Dec 17
A new drug by pharmaceutical giant Eli Lilly rivaling Ozempic and Wegovy could lead to 'significantly' more weight loss after just one year, a trial showcasing initial results has suggested. Read more
Mail Online - Dec 11
A new study reveals that diabetes and weight loss drugs known as GLP-1s are lined with an increased risk of a chronic condition causing chest pain and headache in people with diabetes. Read more
Mail Online - Dec 05
